Skip to Content

    Boston-based drugmaker Vertex, which specializes in rare disorders like cystic fibrosis, doesn’t always attract Big Pharma–level attention. But the firm is on a serious growth trajectory, slated for double-digit expansion in the coming years, per analysts. And the company is branching out into new, brand-name science it hopes can add to its $43 billion market value, including a recent $950 million deal to acquire Semma Therapeutics—a startup that aims to use stem cells to cure Type 1 diabetes.

    Subscribe to Fortune’s Brainstorm Health Daily newsletter, where we monitor advances in healthcare and biopharma.

    Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

    Company Information

    Overall Score2.6
    Sector
    Health Care
    Industry
    Biotechnology
    CEO
    Jeffrey Leiden
    Websitehttps://www.vrtx.com
    HQ Location
    Boston
    Country
    U.S.
    Revenues ($M) (Past 12 Months)$3,454
    Profits ($M) (Past 12 Months)$2,215
    Market Value as of Oct. 9, 2019 ($M)$43,370
    Employees2,500

    Refinitiv Sustainable Leadership Monitor